SCHEMBL22734616

SCHEMBL22734616

CCOC(=O)C(=CNCc1ccc(OC)cc1)C(=O)c1nccc(Cl)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.43
ASPH Q12797 1/20 0.43
KDM8 Q8N371 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.40
LMNA P02545 3/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 3/20 0.39
TP53 P04637 2/20 0.39
KMT2A Q03164 3/20 0.38
GLA P06280 1/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C19 P33261 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
CYP2C9 P11712 1/20 0.38
ATM Q13315 1/20 0.38
P2RY12 Q9H244 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22734614 1.00 KDM4E (0.43) KDM4EASPHKDM8L3MBTL1LMNA
SCHEMBL29454723 1.00 KDM4E (0.43) KDM4EASPHKDM8L3MBTL1LMNA
SCHEMBL22118259 0.82 KDM4E (0.40) KDM4EASPHKDM8L3MBTL1LMNA
SCHEMBL22118260 0.82 KDM4E (0.40) KDM4EASPHKDM8L3MBTL1LMNA
SCHEMBL28711172 0.81 JAK2 (0.38) KDM4EL3MBTL1LMNAMAPTCYP1A2
SCHEMBL22118232 0.79 FNTA (0.35) KDM4EASPHKDM8LMNASMN1; SMN2
SCHEMBL22118241 0.74 NPSR1 (0.39) KDM4ELMNAHPGDSMN1; SMN2MAPT
SCHEMBL29454728 0.74 NPSR1 (0.39) KDM4ELMNAHPGDSMN1; SMN2MAPT
SCHEMBL22118240 0.74 NPSR1 (0.39) KDM4ELMNAHPGDSMN1; SMN2MAPT
SCHEMBL1347480 0.74 LMNA (0.41) KDM4EL3MBTL1LMNAHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448391-B2 Bicyclic derivatives for treating endoparasites ELANCO TIERGESUNDHEIT AG (CH) 2025-10-21 US disclosed
US-20240360116-A1 BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG (SZ) 2024-10-31 US disclosed
EP-4255911-A1 BICYCLIC DERIVATIVES Elanco Tiergesundheit AG (CH) 2023-10-11 EP disclosed
US-20220242857-A1 BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES ELANCO TIERGESUNDHEIT AG (CH) 2022-08-04 US disclosed
WO-2022117783-A1 BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG (CH) 2022-06-09 WO disclosed
CN-114206860-A Bicyclic derivatives for the treatment of endoparasites 礼蓝动物保健有限公司 2022-03-18 CN disclosed
CN-113490527-A Bicyclic derivatives 瑞士伊兰科动物保健有限公司 2021-10-08 CN disclosed
US-20200385398-A1 NEW BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG 2020-12-10 US disclosed
WO-2020247747-A1 BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES ELANCO TIERGESUNDHEIT AG (CH) 2020-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448391-B2 Bicyclic derivatives for treating endoparasites TBXA2R, PIGS, CYCS KDM4E 2087/4885ASPH 3825/4885KDM8 2337/4885
US-20240360116-A1 BICYCLIC DERIVATIVES FABP3, CYCS, TNNI3 KDM4E 2208/4885ASPH 3749/4885KDM8 3126/4885
US-20220242857-A1 BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES TBXA2R, PIGS, CYCS KDM4E 2087/4885ASPH 3825/4885KDM8 2337/4885
US-20200385398-A1 NEW BICYCLIC DERIVATIVES CYCS, FABP3, TNNI3 KDM4E 2550/4885ASPH 3941/4885KDM8 3447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.